260 related articles for article (PubMed ID: 36008411)
1. CK2-induced cooperation of HHEX with the YAP-TEAD4 complex promotes colorectal tumorigenesis.
Guo Y; Zhu Z; Huang Z; Cui L; Yu W; Hong W; Zhou Z; Du P; Liu CY
Nat Commun; 2022 Aug; 13(1):4995. PubMed ID: 36008411
[TBL] [Abstract][Full Text] [Related]
2. OTUD6A orchestrates complex modulation of TEAD4-mediated transcriptional programs.
Kim HJ; Choi Y; Lee Y; Hwangbo M; Kim J
FEBS Lett; 2024 May; 598(9):1045-1060. PubMed ID: 38594215
[TBL] [Abstract][Full Text] [Related]
3. Identification of Small-molecule YAP-TEAD inhibitors by High-throughput docking for the Treatment of colorectal cancer.
Li L; Li R; Wang Y
Bioorg Chem; 2022 May; 122():105707. PubMed ID: 35247806
[TBL] [Abstract][Full Text] [Related]
4. Allosteric Modulation of the YAP/TAZ-TEAD Interaction by Palmitoylation and Small-Molecule Inhibitors.
Mills KR; Misra J; Torabifard H
J Phys Chem B; 2024 Apr; 128(16):3795-3806. PubMed ID: 38606592
[TBL] [Abstract][Full Text] [Related]
5. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
[TBL] [Abstract][Full Text] [Related]
6. The YAP-TEAD4 complex promotes tumor lymphangiogenesis by transcriptionally upregulating CCBE1 in colorectal cancer.
Song J; Dang X; Shen X; Liu Y; Gu J; Peng X; Huang Z; Hong W; Cui L; Liu CY
J Biol Chem; 2023 Apr; 299(4):103012. PubMed ID: 36781122
[TBL] [Abstract][Full Text] [Related]
7. Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner.
Liu Y; Wang G; Yang Y; Mei Z; Liang Z; Cui A; Wu T; Liu CY; Cui L
Oncogene; 2016 May; 35(21):2789-800. PubMed ID: 26387538
[TBL] [Abstract][Full Text] [Related]
8. A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer.
Zhu C; Li L; Zhang Z; Bi M; Wang H; Su W; Hernandez K; Liu P; Chen J; Chen M; Huang TH; Chen L; Liu Z
Mol Cell; 2019 Aug; 75(4):791-806.e8. PubMed ID: 31303470
[TBL] [Abstract][Full Text] [Related]
9. Identification of a derivative of the alkaloid emetine as an inhibitor of the YAP-TEAD interaction and its potential as an anticancer agent.
Sekine S; Takase S; Hayase R; Noritsugu K; Maemoto Y; Ichikawa Y; Ogawa K; Kondoh Y; Osada H; Yoshida M; Ito A
Biosci Biotechnol Biochem; 2023 Apr; 87(5):501-510. PubMed ID: 36809780
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis and Evaluation of a Series of 1,5-Diaryl-1,2,3-triazole-4-carbohydrazones as Inhibitors of the YAP-TAZ/TEAD Complex.
Gibault F; Sturbaut M; Coevoet M; Pugnière M; Burtscher A; Allemand F; Melnyk P; Hong W; Rubin BP; Pobbati AV; Guichou JF; Cotelle P; Bailly F
ChemMedChem; 2021 Sep; 16(18):2823-2844. PubMed ID: 34032019
[TBL] [Abstract][Full Text] [Related]
11. Synthetic molecules targeting yes associated protein activity as chemotherapeutics against cancer.
Iftikhar R; Zahoor AF; Irfan M; Rasul A; Rao F
Chem Biol Drug Des; 2021 Dec; 98(6):1025-1037. PubMed ID: 34587361
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
[TBL] [Abstract][Full Text] [Related]
13. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of TAZ-TEAD complex reveals a distinct interaction mode from that of YAP-TEAD complex.
Kaan HYK; Chan SW; Tan SKJ; Guo F; Lim CJ; Hong W; Song H
Sci Rep; 2017 May; 7(1):2035. PubMed ID: 28515457
[TBL] [Abstract][Full Text] [Related]
15. VGLL4 with low YAP expression is associated with favorable prognosis in colorectal cancer.
Kim JY; Kim EK; Lee WM; Hong YO; Lee H
APMIS; 2020 Oct; 128(10):543-551. PubMed ID: 32794608
[TBL] [Abstract][Full Text] [Related]
16. TEA Domain Transcription Factor 4 Is the Major Mediator of Yes-Associated Protein Oncogenic Activity in Mouse and Human Hepatoblastoma.
Zhang J; Liu P; Tao J; Wang P; Zhang Y; Song X; Che L; Sumazin P; Ribback S; Kiss A; Schaff Z; Cigliano A; Dombrowski F; Cossu C; Pascale RM; Calvisi DF; Monga SP; Chen X
Am J Pathol; 2019 May; 189(5):1077-1090. PubMed ID: 30794805
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic Hedgehog-Smoothened Signaling Depends on YAP1‒TAZ/TEAD Transcription to Restrain Differentiation in Basal Cell Carcinoma.
Yuan Y; Salinas Parra N; Chen Q; Iglesias-Bartolome R
J Invest Dermatol; 2022 Jan; 142(1):65-76.e7. PubMed ID: 34293352
[TBL] [Abstract][Full Text] [Related]
18. Role of the YAP/TAZ-TEAD Transcriptional Complex in the Metabolic Control of TRAIL Sensitivity by the Mevalonate Pathway in Cancer Cells.
El Yousfi Y; Mora-Molina R; López-Rivas A; Yerbes R
Cells; 2023 Sep; 12(19):. PubMed ID: 37830584
[TBL] [Abstract][Full Text] [Related]
19. The TEAD4-YAP/TAZ protein-protein interaction: expected similarities and unexpected differences.
Hau JC; Erdmann D; Mesrouze Y; Furet P; Fontana P; Zimmermann C; Schmelzle T; Hofmann F; Chène P
Chembiochem; 2013 Jul; 14(10):1218-25. PubMed ID: 23780915
[TBL] [Abstract][Full Text] [Related]
20. Convergence of YAP/TAZ, TEAD and TP63 activity is associated with bronchial premalignant severity and progression.
Ning B; Tilston-Lunel AM; Simonetti J; Hicks-Berthet J; Matschulat A; Pfefferkorn R; Spira A; Edwards M; Mazzilli S; Lenburg ME; Beane JE; Varelas X
J Exp Clin Cancer Res; 2023 May; 42(1):116. PubMed ID: 37150829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
